Go Deep
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,005 | 103.7 | 2.16 | 0.61 | 3,507.12 |
| Oct 2026 | 18,981 | 103.9 | 2.16 | 0.61 | 3,480.17 |
| Oct 2026 | 19,295 | 103.7 | 2.16 | 0.61 | 3,457.94 |
| Oct 2026 | 19,281 | 104.0 | 2.16 | 0.61 | 3,456.09 |
| Oct 2026 | 19,303 | 103.8 | 2.16 | 0.61 | 3,449.93 |
| Oct 2026 | 19,302 | 103.8 | 2.16 | 0.61 | 3,441.94 |
| Oct 2026 | 19,302 | 103.8 | 2.16 | 0.61 | 3,445.63 |
| Oct 2026 | 19,295 | 103.9 | 2.16 | 0.61 | 3,449.42 |
| Oct 2026 | 19,304 | 103.8 | 2.16 | 0.61 | 3,436.17 |
| Oct 2026 | 19,302 | 103.8 | 2.16 | 0.61 | 3,430.16 |
Pacira BioSciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 192,399,000.0 | 177,376,000.0 | 196,873,000.0 | 179,516,000.0 |
| Net Profit | 4,653,000.0 | 2,916,000.0 | 1,637,000.0 | 5,432,000.0 |
| EPS | 0.1 | 0.1 | 0.0 | 0.1 |
Pacira BioSciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 726,411,000.0 | 700,966,000.0 | 674,978,000.0 | 666,823,000.0 |
| Net Profit | 7,034,000.0 | -99,560,000.0 | 41,955,000.0 | 15,909,000.0 |
| EPS | 0.2 | -2.1 | 0.9 | 0.3 |
Pacira BioSciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,264,917,000.0 | 1,553,516,000.0 | 1,574,386,000.0 | 1,681,200,000.0 | — |
| Total Liabilities | 571,806,000.0 | 775,168,000.0 | 704,256,000.0 | 906,190,000.0 | — |
| Total Equity | 693,111,000.0 | 778,348,000.0 | 870,130,000.0 | 775,010,000.0 | — |
Owes vs Owns
Pacira BioSciences, Inc. owed $0.46 for every $1 it owned in Jun 2026, down from $0.54 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.46× | 0.45× | 0.50× | 0.45× | 0.54× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Pacira BioSciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 18.8%Receivables 9.8%Inventory 12.1%Fixed assets (tangible) 14.4%Intangible assets 30.7%Other assets 14.1%
How it's funded — Dec 2025
Short-term debt 0.8%Long-term debt 29.4%Payables 1.2%Other liabilities 13.8%Shareholders' equity 54.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 238.4 | 484.6 | 278.6 | 288.7 |
| Receivables | 124.1 | 113.3 | 105.6 | 98.4 |
| Inventory | 152.9 | 125.3 | 104.4 | 96.1 |
| Fixed assets (tangible) | 182.5 | 216.4 | 234.9 | 254.4 |
| Intangible assets | 388.3 | 426.0 | 646.5 | 703.8 |
| Long-term investments | 0.0 | 0.0 | 2.4 | 37.2 |
| Other assets | 178.8 | 188.0 | 202.0 | 202.7 |
| Liabilities & equity | ||||
| Short-term debt | 9.8 | 201.8 | 8.6 | 33.6 |
| Long-term debt | 372.2 | 383.5 | 513.8 | 655.8 |
| Payables | 15.2 | 19.1 | 15.7 | 15.2 |
| Other liabilities | 174.6 | 170.7 | 166.1 | 201.5 |
| Shareholders' equity | 693.1 | 778.3 | 870.1 | 775.0 |
| Net tangible assets | 304.8 | 352.4 | 223.6 | 71.2 |
Pacira BioSciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 151,994,000.0 | 189,389,000.0 | 154,649,000.0 | 145,274,000.0 | — |
| Investing Activities | 99,481,000.0 | -83,276,000.0 | 77,541,000.0 | -225,185,000.0 | — |
| Financing Activities | -369,627,000.0 | 17,363,000.0 | -183,031,000.0 | -401,528,000.0 | — |